OUP user menu

Altered Expression of α-Methylacyl-Coenzyme A Racemase in Prostatic Adenocarcinoma Following Hormone Therapy

Kimiko Suzue MD, PhD, Anthony G Montag MD, Maria Tretiakova MD, PhD, Ximing J. Yang MD, PhD, Sunati Sahoo MD
DOI: http://dx.doi.org/10.1309/H4JX0XEHDAC8YL3P 553-561 First published online: 1 April 2005

Abstract

α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.

Key Words:
  • α-Methylacyl-coenzyme A racemase
  • AMACR
  • Hormone therapy
  • Prostate carcinoma